Holen Sie sich die Stockscreener-App
1.03
2.38%
-0.02
Handel nachbörslich:
1.03
Schlusskurs vom Vortag:
$1.05
Offen:
$1.02
24-Stunden-Volumen:
1.52M
Relative Volume:
1.51
Marktkapitalisierung:
$133.05M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.91M
KGV:
-4.6818
EPS:
-0.22
Netto-Cashflow:
$-19.57M
1W Leistung:
+1.49%
1M Leistung:
+22.05%
6M Leistung:
+61.54%
1J Leistung:
-27.82%
1-Tages-Spanne:
$0.9604
$1.06
1-Wochen-Bereich:
$0.9604
$1.29
52-Wochen-Spanne:
$0.5526
$1.66
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Firmenname
Atossa Therapeutics Inc
Sektor
Branche
Telefon
206.588.0256
Adresse
10202 5TH AVENUE NE, SEATTLE, WA
Vergleichen Sie ATOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
1.03 | 135.63M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-01-26 | Eingeleitet | Maxim Group | Buy |
Atossa Therapeutics Inc Aktie (ATOS) Neueste Nachrichten
Atossa Therapeutics, Inc. Appoints Mark Daniel as Chief Financial Officer - MarketScreener
Atossa appoints Mark Daniel as CFO to prepare for commercial operations By Investing.com - Investing.com South Africa
Atossa Therapeutics Appoints New Chief Financial Officer - TipRanks
Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness - PR Newswire
Atossa Therapeuticsappoints Mark Daniel as CFOSEC filing - MarketScreener
What MACD and RSI say about Atossa Therapeutics Inc.CEO Change & Growth Oriented Trading Recommendations - newser.com
Can Atossa Therapeutics Inc. stock sustain market leadershipQuarterly Risk Review & Safe Capital Growth Stock Tips - newser.com
Intraday pattern recognizer results for Atossa Therapeutics Inc.Insider Buying & Real-Time Market Trend Scan - newser.com
What moving averages say about Atossa Therapeutics Inc.July 2025 Spike Watch & Daily Market Momentum Tracking - newser.com
Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals - StreetInsider
How Atossa Therapeutics Inc. stock trades before earnings2025 Support & Resistance & Fast Gain Swing Alerts - newser.com
Will Atossa Therapeutics Inc. stock split again soonMarket Activity Report & Reliable Volume Spike Alerts - newser.com
Applying big data sentiment scoring on Atossa Therapeutics Inc.Gold Moves & AI Driven Stock Movement Reports - newser.com
Will Atossa Therapeutics Inc. stock benefit from commodity pricesJuly 2025 Macro Moves & Free Technical Pattern Based Buy Signals - newser.com
Published on: 2025-10-13 08:27:23 - newser.com
Atossa Therapeutics (ATOS) Strengthens Patent Portfolio for Z-en - GuruFocus
Israeli patent No. 304863 for Z-endoxifen — Atossa secures enteric 90% purity, dose & manufacturing claims - Stock Titan
Can Atossa Therapeutics Inc. (YAG2) stock stage a strong rebound this quarterChart Signals & Safe Entry Point Alerts - newser.com
Regression analysis insights on Atossa Therapeutics Inc. performancePortfolio Gains Summary & High Accuracy Trade Signal Alerts - newser.com
Can a trend reversal in Atossa Therapeutics Inc. lead to recoveryEarnings Growth Report & Stepwise Swing Trade Plans - newser.com
NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Newport Daily News
Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Pueblo Chieftain
Is Atossa Therapeutics Inc. stock ready for a breakoutJuly 2025 Sector Moves & Breakout Confirmation Alerts - newser.com
How to forecast Atossa Therapeutics Inc. trends using time seriesGap Down & Weekly Market Pulse Updates - newser.com
Is Atossa Therapeutics Inc. stock entering bullish territoryMarket Growth Report & Fast Moving Stock Trade Plans - newser.com
Comparing Atossa Therapeutics Inc. in custom built stock radars2025 Earnings Surprises & Stepwise Entry and Exit Trade Signals - newser.com
Published on: 2025-10-10 02:05:17 - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for Atossa Genetics (NASDAQ:ATOS) - MarketBeat
Can Atossa Therapeutics Inc. (YAG2) stock deliver double digit returnsOptions Play & Weekly Breakout Watchlists - newser.com
Signal strength of Atossa Therapeutics Inc. stock in tech scannersTrade Entry Report & Weekly Momentum Picks - newser.com
Can Atossa Therapeutics Inc. (YAG2) stock reach $200 price targetQuarterly Trade Report & Low Volatility Stock Recommendations - newser.com
Atossa Therapeutics (ATOS) Announces Upcoming Virtual Meeting - GuruFocus
Atossa streamlines breast cancer trial to focus on 2026 NDA plans - Investing.com
Atossa Therapeutics streamlines Evangeline breast cancer clinical trial to prioritize for 2026 NDA-enabling activities - MarketScreener
Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities - PR Newswire
Atossa Therapeutics Inc. stock retracement – recovery analysisEarnings Growth Report & Free Fast Gain Swing Trade Alerts - newser.com
Can Atossa Therapeutics Inc. stock hit analyst price targetsWeekly Risk Report & Consistent Income Trade Recommendations - newser.com
Atossa Therapeutics appoints Janet Rea as SVP of R&D By Investing.com - Investing.com Nigeria
Atossa Therapeutics appoints Janet Rea as SVP of R&D - Investing.com
What drives Atossa Therapeutics Inc YAG2 stock priceDouble Top/Bottom Patterns & Superior Trading Ideas - earlytimes.in
Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones - StreetInsider
Veteran Drug Approval Expert Returns to Atossa Therapeutics to Advance Breakthrough Breast Cancer Treatment - Stock Titan
Finanzdaten der Atossa Therapeutics Inc-Aktie (ATOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Atossa Therapeutics Inc-Aktie (ATOS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Remmel H. Lawrence | Director |
Mar 26 '25 |
Buy |
0.70 |
10,000 |
7,000 |
10,257 |
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):